Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 14/09/2026 +03			5-day change	1st Jan Change
7.510 ^USD	+2.60%		-8.41%	-2.72%

09-14	RTW Biotech NAV rises 15% as public investments drive returns	AN
09-08	Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers	CI

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

e057994272db24622f41d.VB6tzjR8t_E0Pbw-LfXf-4ffI7EcVdLi4lnQ0SWjsfA.Pizqv3FP1ZdZVe0KTqSTgtGYSNNyeOSup2y2v0GR5IYlW9uqcRP_tnVQ8Q~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
07-07	RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating	MT
06-24	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says	MT
05-14	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
01-08	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
11-05	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
19/10/25	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
26/08/25	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
15/08/25	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
08/08/25	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25/06/25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
09/05/25	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
09/05/25	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
09/05/25	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
28/04/25	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
10/04/25	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
08/04/25	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT
21/03/25	RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
31/01/25	B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating	MT
07/01/25	RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk	MT
31/12/24	BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating	MT
18/12/24	Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating	MT
30/09/24	Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+99.73%
	WUXI APPTEC CO., LTD.					+17.76%
	ARGENX SE					+17.76%
	INSMED INCORPORATED					+59.76%
	WUXI BIOLOGICS (CAYMAN) INC.					+18.28%
	BIONTECH SE					+19.67%
	GENMAB A/S					+15.96%
	PHARMAESSENTIA CORPORATION					+17.42%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+28.78%
	SUMMIT THERAPEUTICS INC.					+57.67%
	Average					+35.28%
	Weighted average by Cap.					+24.91%